Readers React: What to Expect After the Supreme Court’s Hikma Ruling, IPWatchdog
June 07, 2026IPWatchdog quoted partner Maarika Kimbrell in an article examining the US Supreme Court’s unanimous decision in Hikma v. Amarin and its implications for the pharmaceutical industry, particularly the continued viability of the Hatch-Waxman Act’s skinny label pathway.
The article gathered perspectives from stakeholders across the life sciences and intellectual property communities following the Court’s ruling, which reaffirmed protections for generic drug manufacturers using carved-out labels. Maarika noted that while the decision reinforces an important mechanism for generic competition, policymakers must continue to balance incentives for innovation with the benefits of market competition. She observed that FDA and Congress have long recognized the value of encouraging the development of new uses for existing therapies and suggested that regulators should continue evaluating whether adjustments are needed to maintain that balance.
“As with everything in the Hatch-Waxman space, a careful balance between innovation and competition needs to be maintained for the system to work properly,” Maarika said.